Omoleye, Olasubomi J.
Freeman, Jincong Q.
Oluwasanu, Mojisola
Adeniji-Sofoluwe, Adenike
Woodard, Anna E.
Aribisala, Benjamin S.
Adejumo, Prisca O.
Ntekim, Atara
Makumbi, Timothy
Ndom, Paul
Ajayi, IkeOluwapo O.
Olopade, Olufunmilayo I.
Huo, Dezheng
Funding for this research was provided by:
Susan G. Komen (TREND21675016, Komen Scholar)
National Institutes of Health (R01CA089085, U01CA161032)
Article History
Received: 28 August 2023
Accepted: 27 November 2023
First Online: 5 January 2024
Declarations
:
: Olufunmilayo I. Olopade is a co-founder of CancerIQ, sits on the advisory boards of 54gene and Tempus, and has received research funding from Ayala Pharmaceuticals, Cepheid, Color Genomics, Novartis, and Roche/Genentech. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committees of The University of Ibadan, The University of Chicago, The University of Kampala, and the University of Yaoundé.
: Written informed consent was obtained from all individual participants included in the study.